Loteprednol

Summary

Loteprednol (CHEMBL1201389) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 5
• Chemistry: 346.4 Da · C20H26O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201389
Name	Loteprednol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	7092779
Molecular formula	C20H26O5
Molecular weight	346.4
InChIKey	MCKJPJYRCPANCC-XLXYOEISSA-N

SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)O)O)CCC4=CC(=O)C=C[C@]34C)O

IUPAC name: (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylic acid

Also known as: Loteprednol, LOTEPREDNOL, loteprednol

Patent coverage: 15 distinct patent families (46 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00817557	PHASE4	UNKNOWN	Use of Loteprednol for Contact Lens Intolerance and Dryness
NCT01456780	PHASE4	COMPLETED	Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
NCT02974387	PHASE4	UNKNOWN	Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study
NCT01028027	PHASE3	COMPLETED	Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
NCT01344226	Not specified	COMPLETED	Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).